Non-invasive tests for resmetirom treatment fail to accurately define the target population: Evidence from a biopsy-proven MASLD cohort. [PDF]
Kaya E +6 more
europepmc +1 more source
Clinical utility of the MAF-5 score for assessing MAFLD/MASLD in a Japanese population with obesity. [PDF]
Fukumitsu H +10 more
europepmc +1 more source
Association of noninvasive tests of liver fibrosis with chronic kidney disease in MASLD: a systematic review and meta-analysis. [PDF]
Sethasine S +4 more
europepmc +1 more source
Assessment of the diagnostic efficacy of five non-invasive tests for MASLD: external validation utilizing data from two cohorts. [PDF]
Zou H, Pan W, Sun X.
europepmc +1 more source
Editorial: Implementing Risk Assessment Tools for MetALD in Clinical Practice. [PDF]
Ochoa-Allemant P, Serper M.
europepmc +1 more source
In Vitro Evaluation of the Efficacy of 27 French Over-the-Counter Anti-lice Treatments. [PDF]
Toubate B +3 more
europepmc +1 more source
Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection. [PDF]
Bhatti TK, Lim JK.
europepmc +1 more source
Real-World Assessment of Liver Corrected T1 and Magnetic Resonance Elastography in Predicting Liver Disease Progression. [PDF]
Corey KE +10 more
europepmc +1 more source
Non-invasive tests fail to ensure therapeutic precision for resmetirom in MASLD. [PDF]
Adali G, Akdogan RA.
europepmc +1 more source
openaire +2 more sources

